Edgar Filing: Cardiogenesis Corp /CA - Form 10-Q

Cardiogenesis Corp /CA Form 10-Q August 09, 2010

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

DESCRIPTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2010.

o TRANSITION REP	ORT PURSUAN	Γ TO SECTION 1	13 OR 15(D) OF	THE SECURITIES
EXCHANGE ACT	OF 1934		, ,	
For the transition period from	to			
	Commission	n file number 0-28	3288	

CARDIOGENESIS CORPORATION

(Exact name of registrant as specified in its charter)

California 77-0223740

(State of incorporation or organization)

(I.R.S. Employer Identification Number)

11 Musick Irvine, California 92618

(Address of principal executive offices)

(949) 420-1800

(Issuer s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes b No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act:

Large accelerated Accelerated filer o Non-accelerated filer o Smaller reporting filer o (Do not check if a smaller reporting company b company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No b

As of July 31, 2010, there were 46,732,481 shares of the registrant s common stock, no par value, outstanding.

Table of Contents 2

CARDIOGENESIS CORPORATION TABLE OF CONTENTS

		Page
	<u>PART I</u>	
	FINANCIAL INFORMATION	
Item 1.	Financial Statements:	
	Condensed consolidated balance sheets as of June 30, 2010 (unaudited) and December 31,	
	2009 (audited)	3
	Unaudited condensed consolidated statements of operations for the three and six months	
	ended June 30, 2010 and 2009	4
	Unaudited condensed consolidated statements of cash flows for the six months ended	
	June 30, 2010 and 2009	5
	Notes to unaudited condensed consolidated financial statements	6
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	13
<u>Item 4(T).</u>	Controls and Procedures	17
	PART II	
	OTHER INFORMATION	
Item 1.	Legal Proceedings	19
Item 6.	Exhibits	19
	<u>Signatures</u>	20
	Certifications	
EX-31.1		
EX-31.2		
EX-32.1 EX-32.2		
<u>LA-32.2</u>	2	
	2	

Table of Contents

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

CARDIOGENESIS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)

	:	June 30, 2010 (unaudited)		December 31, 2009 (audited)	
ASSETS	`	,	`	,	
Current assets: Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of \$6 Inventories	\$	2,195 1,054 817	\$	2,568 933 914	
Prepaids and other current assets		215		253	
Total current assets Property and equipment, net Other assets, net		4,281 280 9		4,668 341 9	
Total assets	\$	4,570	\$	5,018	
LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities:					
Accounts payable	\$	243	\$	127	
Accrued salaries and related		564		604	
Accrued liabilities		313		299	
Deferred revenue		787		744	
Note payable				88	
Current portion of capital lease obligations		10		9	
Total current liabilities Capital lease obligations, less current portion		1,917 9		1,871	

Table of Contents 4